Figure EV1. Extended LMP7 inhibition in human PBMC .

• A
  PBMCs were treated with PRN1126 at 1 μM for 1 h, washed to remove compound, and incubated in media for the time indicated. LMP7 inhibition was determined by hydrolysis of fluorogenic substrate (Suc‐LLVY‐AMC). Data points represent the mean ± s.d. (n = 3).
• B–G
  Hydrolysis of fluorogenic substrates Bz‐VGR‐AMC for trypsin‐like activity (B–E) or z‐LLE‐βNA for caspase‐like activity (F, G) of human (B, C, F) or mouse (D, E, G) 20S constitutive proteasome (B, D, F, G) or immunoproteasome (C, E) at various concentrations of PRN1126 and MG132. Data are presented as the means of fluorescence ± s.d. from quadruplicate assays. The experiments were repeated three times with similar results.